Bradley Hickey,Nimfa Teneza-Mora,Joanne Lumsden,Sharina Reyes,Martha Sedegah,Lindsey Garver,Michael R. Hollingdale,Jo Glenna Banania,Harini Ganeshan,Megan Dowler,Anatalio Reyes,Cindy Tamminga,Alexandra Singer,Alicia Simmons,Maria Belmonte,Arnel Belmonte,Jun Huang,Sandra Inoue,Rachel Velasco,Steve Abot,Carlos S. Vasquez,Ivelese Guzman,Mimi Wong,Patrick Twomey,Mariusz Wojnarski,James Moon,Yolanda Alcorta,Santina Maiolatesi,Michele Spring,Silas Davidson,Sidhartha Chaudhury,Eileen Villasante,Thomas L. Richie,Judith E. Epstein

Abstract:BACKGROUND: Immunization with radiation-attenuated sporozoites (RAS) by mosquito bite provides >90% sterile protection against Plasmodium falciparum (Pf) malaria in humans. RAS invade hepatocytes but do not replicate. CD8+ T cells recognizing parasite-derived peptides on the surface of infected hepatocytes are likely the primary protective mechanism. We conducted a randomized clinical trial of RAS immunization to assess safety, to achieve 50% vaccine efficacy (VE) against controlled human malaria infection (CHMI), and to generate reagents from protected and non-protected subjects for future identification of protective immune mechanisms and antigens.METHODS: Two cohorts (Cohort 1 and Cohort 2) of healthy, malaria-naïve, non-pregnant adults age 18-50 received five monthly immunizations with infected (true-immunized, n = 21) or non-infected (mock-immunized, n = 5) mosquito bites and underwent homologous CHMI at 3 weeks. Immunization parameters were selected for 50% protection based on prior clinical data. Leukapheresis was done to collect plasma and peripheral blood mononuclear cells.RESULTS: Adverse event rates were similar in true- and mock-immunized subjects. Two true- and two mock-immunized subjects developed large local reactions likely caused by mosquito salivary gland antigens. In Cohort 1, 11 subjects received 810-1235 infected bites; 6/11 (55%) were protected against CHMI vs. 0/3 mock-immunized and 0/6 infectivity controls (VE 55%). In Cohort 2, 10 subjects received 839-1131 infected bites with a higher first dose and a reduced fifth dose; 9/10 (90%) were protected vs. 0/2 mock-immunized and 0/6 controls (VE 90%). Three/3 (100%) protected subjects administered three booster immunizations were protected against repeat CHMI vs. 0/6 controls (VE 100%). Cohort 2 uniquely showed a significant rise in IFN-γ responses after the third and fifth immunizations and higher antibody responses to CSP.CONCLUSIONS: PfRAS were generally safe and well tolerated. Cohort 2 had a higher first dose, reduced final dose, higher antibody responses to CSP and significant rise of IFN-γ responses after the third and fifth immunizations. Whether any of these factors contributed to increased protection in Cohort 2 requires further investigation. A cryobank of sera and cells from protected and non-protected individuals was generated for future immunological studies and antigen discovery.TRIAL REGISTRATION: ClinicalTrials.gov NCT01994525.

R21 malaria vaccine is protective against intradermal but not intravenous Plasmodium falciparum sporozoites in a randomized controlled human malaria infection study in Kenyan adults

Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.

Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya

Functional Human IgA Targets a Conserved Site on Malaria Sporozoites

Safety and Efficacy of a Monoclonal Antibody Against Malaria in Mali.

Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine

Naturally Acquired Antibodies Specific for Plasmodium Falciparum Reticulocyte-Binding Protein Homologue 5 Inhibit Parasite Growth and Predict Protection from Malaria.

A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates

Safety and protective efficacy of PfSPZ Vaccine administered to HIV-negative and -positive Tanzanian adults

Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine development

Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria challenge

IMRAS—A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents

Sporozoite immunization: Innovative Translational Science to Support the Fight against malaria

PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial

PfSPZ Vaccine induces focused humoral immune response in HIV positive and negative Tanzanian adults

IMRAS-Immunization with Radiation-Attenuated Plasmodium Falciparum Sporozoites by Mosquito Bite: Cellular Immunity to Sporozoites, CSP, AMA1, TRAP and CelTOS

Mapping of safe and early chemo-attenuated live Plasmodium falciparum immunization identifies immune signature of vaccine efficacy

Identification of RTS,S/AS01 vaccine–induced humoral biomarkers predictive of protection against controlled human malaria infection

Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection

The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study

Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection